The United States Food and Drug Administration (FDA) has received a request for Emergency Use Authorisation from NeuroRx Inc, a clinical stage, small molecule pharmaceutical company, for its RLF-100™ aviptadil, it was reported on Wednesday.
RLF-100 aviptadil is intended for patients with Critical COVID-19 and Respiratory Failure who are receiving intensive care and who have exhausted all approved treatments. The product is being developed by NeuroRx as part of a global collaboration with Relief Therapeutics Holdings, SA (SIX:RLF;OTCQB:RLFTF).
The company has submitted the application based on a case-control study that compared patients who were treated with RLF-100 (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with the product indicated a threefold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement.
The company has submitted the results to a peer-reviewed journal.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older